SAR 3 Billion Agreement Signed To Enhance Gene Therapy Manufacturing In Saudi Arabia

King Fahad Medical City (KFMC) has partnered with Boston Oncology to set up a state-of-the-art manufacturing unit for T-cell immunotherapy. This facility will adhere to good manufacturing practices (GMP) and utilise a closed clean system. The collaboration, worth over SAR 3 billion, is part of Saudi Vision 2030's aim to enhance public health and life expectancy.

The agreement was formalised during the Global Health Exhibition 2024, which took place from October 21 to 23. This initiative aligns with the Kingdom’s Health Sector Transformation Program and Vision 2030 objectives. It aims to improve recovery rates for acute lymphoblastic leukemia patients by 50% while cutting treatment costs by 30%.

T cells, also known as T lymphocytes or thymocytes, are crucial white blood cells in the immune system. The new facility at KFMC will significantly reduce cell manufacturing time by over half. This improvement will enhance treatment effectiveness and support research in immunotherapy and gene therapy for cancer.

The project is designed to foster a robust research environment in the field of advanced therapies. By doing so, it aims to position Saudi Arabia as a global leader in immunotherapy and gene therapy. The agreement spans 25 years, reflecting a long-term commitment to innovation and healthcare improvement.

This collaboration is expected to bolster the Kingdom's standing in advanced medical treatments. It supports the broader goals of Saudi Vision 2030, which include improving quality of life and increasing life expectancy through better healthcare solutions.

The initiative not only focuses on enhancing recovery rates but also aims at reducing costs associated with current treatments. By cutting down on cell manufacturing time, the project seeks to make therapies more efficient and accessible.

Overall, this agreement represents a significant step towards achieving strategic healthcare goals within Saudi Arabia. It underscores the Kingdom's dedication to advancing its medical capabilities and fostering an innovative research environment.

With inputs from SPA